Network scientists identify 40 new drugs to test against COVID-19
Northeastern researchers have identified 40 new potential drugs that could treat COVID-19.
The findings, reported via Northeastern’s Center for Complex Network Science Research on Wednesday, come from a modeling tool for infection dynamics based on network science—complex math, physics, and computing.
The toolset mapped the way proteins within human cells behave after a cell is hijacked with SARS-CoV-2, the new coronavirus that causes the COVID-19 illness.
“We have prioritized many more drugs, but there are 40 that we are actually trying to move forward,” says Albert-László Barabási, Robert Gray Dodge Professor of Network Science and University Distinguished Professor of physics at Northeastern.
Albert-László Barabási, Robert Gray Dodge Professor of Network Science and University Distinguished Professor of physics at Northeastern. Photo by Adam Glanzman/Northeastern University
Barabási’s team is already in discussions with experimental biologists at Harvard to begin testing these drugs in human cell lines.
The interactions of different kinds of proteins within our cells play a key role in orchestrating the complex biochemical reactions that control our bodies. That’s why, Barabási says, the best way to understand how viruses spread is to identify the whole set of the molecular interactions within human cells, and the networks those interactions create as proteins interact with genetic material inside the cell.
“Virtually every disease that we have spreads through a cellular network,” he says. “The virus has a particularly fast way of doing that because it is invading the cell, in this case with 26 proteins, effectively doing a very fast and effective perturbation on multiple points of the network.”
The model, which Barabási originally developed with a group of researchers in 2012 to study other human viruses, also predicted that SARS-CoV-2 could potentially attack cells in the brain. That finding, the report states, could help explain recent reports that early COVID-19 symptoms include the loss of the sense of smell and taste.
The new list of drugs adds to other potential treatments that researchers have already identified. Barabási’s model identified several of those drugs, as well as others that had not been considered.
“The reason we can do so is because we are not limiting ourselves to drugs that hit those proteins that the virus targets,” Barabási says. “We can also discover drugs that hit in the neighborhood that the virus targets.”
Quickly after entering the body, SARS-CoV-2 hijacks human cells and retools them into virus-replicating machines. The virus relies on the set of protruding proteins for which all other strains of coronaviruses are named—a set of spikes resembling those of a crown. As those viral proteins latch on to the proteins of a healthy cell, they disrupt basic functions within it, and make it churn out millions more versions of the virus.
The first step in modeling viral infection was understanding which proteins SARS-CoV-2 attacks to hijack human cells. Researchers recently reported that there are 332 of those proteins.
Barabási’s toolset modeled the role of the 332 proteins targeted by the coronavirus and predicted other mechanisms those proteins could trigger within the cell to lead to the symptoms of COVID-19.
The model focused on drugs that could fight the virus not just by neutralizing its spike proteins as they first targeted human cells, but by disrupting other interactions within human proteins and genes. These treatments target areas within the cell where the virus works, instead of directly targeting the virus, and could influence the way the proteins that SARS-CoV-2 needs to thrive are encoded.
“By simply identifying what neighborhood the virus hits, we can identify what are the potential drugs that are hitting in the same neighborhood, and therefore could be effective against the virus,” Barabási says.
And, he says, the best drug candidates will probably be those that don’t target the proteins that SARS-CoV-2 initially attacks but work within the same subcellular neighborhood.
“Very few drugs on the market are directly targeting the disease proteins themselves,” Barabási says. “Simply knowing what proteins the virus targets will not be enough for us to find the drug, we need to understand very well the network’s neighborhoods of those hitting points.”
Marinka Zitnik, an assistant professor of biomedical informatics at Harvard Medical School, used machine learning to help Barabási’s group comb through available data on drugs already on the market or in clinical trials that could be repurposed to treat COVID-19.
Joseph Loscalzo, Hersey Professor of the Theory and Practice of Medicine at Harvard Medical School, chairman of the Department of Medicine, and physician-in-chief at Brigham and Women’s Hospital, helped the team discard potential drug candidates that could be significantly toxic or impossible to administer intravenously or orally.
The team’s progress and updates are being released online as soon as they are available, in an effort to help the global scientific community as it works at breakneck speed to solve the COVID-19 crisis. A report with more data and information will be released as a preprint online and submitted to a peer-reviewed journal for publication, Barabási says.
“We are releasing the results as they emerge so that others can immediately build on them and have the research,” he says. “There is such an imminent need to make progress in this area, that we cannot be slaves of our existing academic or business models.”
For media inquiries, please contact Shannon Nargi at s.nargi@northeastern.edu or 617-373-5718.
Northeastern models are helping shape US COVID-19 policy
Northeastern researchers are part of the network of teams creating models to advise the Trump administration on the COVID-19 outbreak in the U.S., White House officials said Tuesday. They said data from the models formed the basis of the decision to extend “social distancing” guidelines through April.
Read moreWhat China can teach us about managing the COVID-19 pandemic
Northeastern researchers joined forces with colleagues around the globe to analyze the efforts to control the COVID-19 outbreak in China. Their findings provide a roadmap for other countries to follow.
Read more‘Social distancing’ is only the first step toward stopping the COVID-19 pandemic
After days of closures and requests—or orders—to stay home, many people caught in the heart of the COVID-19 pandemic are wondering if these efforts will be enough. Network scientist Alessandro Vespignani says the answer depends on the ways that local, regional, and federal governments use the time.
Read moreTime is precious. Drugs are, too. How can hospitals make the most of both to battle COVID-19?
To prepare for an influx of patients in the COVID-19 pandemic, hospitals should strive to cut wait times, move to virtual care, and work closely with pharmacists to predict the availability of certain drugs, says Jacqueline Griffin, an assistant professor of engineering who specializes in healthcare optimization.
Read moreUnsure what to do about COVID-19? Take this 60-minute course.
COVID-19: How to be Safe and Resilient, an hour-long course that is free and accessible to anyone, was launched Friday morning by Northeastern’s Global Resilience Institute. Its purpose is to make reliable skills for surviving the pandemic available in one place.
Read morePeople who might have COVID-19 are benefiting from virtual healthcare. Everyone else may, too.
To avoid overcrowding waiting rooms, U.S. hospitals and doctors’ are screening patients remotely for symptoms of COVID-19. This widespread adaptation of telemedicine may help patients during the pandemic, and will almost certainly help other people down the road, says Janet Rico, who is leading a team of researchers to establish best practices for virtual care.
Read moreThe global medical supply chain is not immune to COVID-19
“We’re all so used to going to CVS and whatever we need is there,” says Nada Sanders, Distinguished Professor of supply chain management. The pandemic is reminding us not to take those things for granted.
Read moreCompanies can help employees working remotely during the COVID-19 pandemic
In response to the rapid spread of COVID-19, some companies are requiring their employees to work remotely. But managers should account for several potential obstacles, says management professor Barbara Larson.
Read moreClosing borders can delay, but can’t stop the spread of COVID-19, new report says
Travel restrictions will not stop the spread of COVID-19, but observing quarantines and avoiding public events gives us a chance to slow the epidemic, says Matteo Chinazzi, a research scientist in the Network Science Institute. “Closing airports will buy you time, but it’s not enough.”
Read moreOne way to predict the spread of COVID-19? Follow the memes.
Network scientist Samuel Scarpino shows how epidemiologists can more comprehensively map infectious disease outbreaks, which follow the same complex spreading patterns as social trends.
Read moreHere’s why we shouldn’t refer to COVID-19 as simply ‘coronavirus’
Since mid-February, the disease caused by the coronavirus has been known as COVID-19, short for coronavirus disease 2019, though “coronavirus” is still often used as shorthand to refer to the disease. That’s not entirely accurate.
Read moreHow can we stop the spread of false rumors about COVID-19? Better math.
Rumors travel fast, just like all information on the internet. Northeastern professor Alessandro Vespignani and doctoral student Jessica Davis want to model how those rumors spread, as well as the conditions that allow for their propagation.
Read more
